NO770854L - Fremgangsm}te for fremstilling av histamin h2-antagonister - Google Patents
Fremgangsm}te for fremstilling av histamin h2-antagonisterInfo
- Publication number
- NO770854L NO770854L NO770854A NO770854A NO770854L NO 770854 L NO770854 L NO 770854L NO 770854 A NO770854 A NO 770854A NO 770854 A NO770854 A NO 770854A NO 770854 L NO770854 L NO 770854L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- het
- hydrogen
- compounds
- lower alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title description 13
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 29
- 239000002253 acid Chemical group 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 10
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 5
- 229910052727 yttrium Inorganic materials 0.000 claims description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 229910052760 oxygen Chemical group 0.000 claims description 3
- 239000001301 oxygen Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims description 2
- FUMLVQBLTDARNM-UHFFFAOYSA-N 2-amino-2-oxoethanethioic s-acid Chemical compound NC(=O)C(S)=O FUMLVQBLTDARNM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910003439 heavy metal oxide Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- -1 4-imidazolyl ring Chemical group 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 8
- JEOZNMMOIBLWLV-UHFFFAOYSA-N 2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine Chemical compound CC=1N=CNC=1CSCCN JEOZNMMOIBLWLV-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- WAIHMWWSWLOHNH-UHFFFAOYSA-N 2-(1,3-thiazol-2-ylmethylsulfanyl)ethanamine Chemical compound NCCSCC1=NC=CS1 WAIHMWWSWLOHNH-UHFFFAOYSA-N 0.000 description 2
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 2
- GINGNNBPJPKZAP-UHFFFAOYSA-M potassium;2-amino-2-oxoethanethioate Chemical compound [K+].NC(=O)C([O-])=S GINGNNBPJPKZAP-UHFFFAOYSA-M 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- NHLYJWQBMZKFBT-UHFFFAOYSA-N 2-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethylamino]-2-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethylimino]acetic acid Chemical compound N1C=NC(CSCCNC(=NCCSCC2=C(NC=N2)C)C(O)=O)=C1C NHLYJWQBMZKFBT-UHFFFAOYSA-N 0.000 description 1
- LGHXLYOZKCMYHZ-UHFFFAOYSA-N 2-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethylamino]-2-methyliminoacetic acid;hydrochloride Chemical compound Cl.CNC(C(O)=O)=NCCSCC=1N=CNC=1C LGHXLYOZKCMYHZ-UHFFFAOYSA-N 0.000 description 1
- NWYNBLNMIOBXJV-UHFFFAOYSA-N 2-amino-2-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethylimino]acetic acid Chemical compound CC=1NC=NC=1CSCCNC(=N)C(O)=O NWYNBLNMIOBXJV-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- FPBPLBWLMYGIQR-UHFFFAOYSA-N Metiamide Chemical compound CNC(=S)NCCSCC=1N=CNC=1C FPBPLBWLMYGIQR-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- HBPSYKUUBQFJEO-UHFFFAOYSA-N [2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethylamino]-methyliminomethanesulfinic acid Chemical compound CNC(S(O)=O)=NCCSCC=1N=CNC=1C HBPSYKUUBQFJEO-UHFFFAOYSA-N 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- RLJMLMKIBZAXJO-UHFFFAOYSA-N lead nitrate Chemical compound [O-][N+](=O)O[Pb]O[N+]([O-])=O RLJMLMKIBZAXJO-UHFFFAOYSA-N 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDZCMNKCNXVTIK-UHFFFAOYSA-N sulfonylmethanediamine Chemical class NC(N)=S(=O)=O KDZCMNKCNXVTIK-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- FYOWZTWVYZOZSI-UHFFFAOYSA-N thiourea dioxide Chemical class NC(=N)S(O)=O FYOWZTWVYZOZSI-UHFFFAOYSA-N 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9750/76A GB1574214A (en) | 1976-03-11 | 1976-03-11 | Amidines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO770854L true NO770854L (no) | 1977-09-13 |
Family
ID=9878056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO770854A NO770854L (no) | 1976-03-11 | 1977-03-10 | Fremgangsm}te for fremstilling av histamin h2-antagonister |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US4118502A (es) |
| JP (1) | JPS52136170A (es) |
| AR (2) | AR218242A1 (es) |
| AT (1) | AT358576B (es) |
| AU (1) | AU506146B2 (es) |
| BE (1) | BE852324A (es) |
| CA (1) | CA1075700A (es) |
| CS (1) | CS196352B2 (es) |
| DD (1) | DD128616A5 (es) |
| DE (1) | DE2710326A1 (es) |
| DK (1) | DK96477A (es) |
| ES (1) | ES456735A1 (es) |
| FI (1) | FI770736A (es) |
| FR (1) | FR2343730A1 (es) |
| GB (1) | GB1574214A (es) |
| GR (1) | GR62562B (es) |
| HU (1) | HU176611B (es) |
| IE (1) | IE44786B1 (es) |
| IL (1) | IL51530A (es) |
| IN (1) | IN147036B (es) |
| IT (1) | IT1075494B (es) |
| LU (1) | LU76930A1 (es) |
| MW (1) | MW977A1 (es) |
| NL (1) | NL7702533A (es) |
| NO (1) | NO770854L (es) |
| NZ (1) | NZ183396A (es) |
| OA (1) | OA05595A (es) |
| PL (1) | PL105620B1 (es) |
| PT (1) | PT66255B (es) |
| RO (1) | RO73006A (es) |
| SE (1) | SE7702771L (es) |
| SU (2) | SU814274A3 (es) |
| ZA (1) | ZA771018B (es) |
| ZM (1) | ZM2677A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4210658A (en) * | 1977-09-08 | 1980-07-01 | Smith Kline & French Laboratories Limited | Amidinosulphonic acid derivatives |
| EP0006679B1 (en) | 1978-05-24 | 1982-07-21 | Imperial Chemical Industries Plc | Antisecretory thiadiazole derivatives, processes for their manufacture and pharmaceutical compositions containing them |
| IL57415A (en) * | 1978-05-30 | 1984-08-31 | Smith Kline French Lab | Nitropyrrole compounds,process for preparing them and pharmaceutical compositions containing them |
| US4282213A (en) * | 1978-06-06 | 1981-08-04 | Smith Kline & French Laboratories Limited | Amidino and guanidino phosphonates |
| US4242351A (en) * | 1979-05-07 | 1980-12-30 | Imperial Chemical Industries Limited | Antisecretory oxadiazoles and pharmaceutical compositions containing them |
| IT8020734A0 (it) * | 1980-03-18 | 1980-03-18 | Turconi Franco | Quadrata (2 aminoetil)-tiometilderivati del 4-metil-5 aperta par.chiusa par. quadrata-imidazolo adattivita' terapeutica. |
| US4382090A (en) * | 1980-10-02 | 1983-05-03 | Eli Lilly And Company | N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds |
| US4375547A (en) * | 1980-10-02 | 1983-03-01 | Eli Lilly And Company | N-Methyl-N'-2-([(2-dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine |
| IT1201523B (it) * | 1982-05-18 | 1989-02-02 | Angeli Inst Spa | Eterociclilfenilfomramidine,processi per la loro preparazione e loro uso farmaceutico |
| US5399706A (en) * | 1993-03-02 | 1995-03-21 | H. B. Fuller Licensing & Financing, Inc. | Imidazolidinone diamine and derivatives thereof |
| WO2022034121A1 (en) | 2020-08-11 | 2022-02-17 | Université De Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE758146A (fr) * | 1969-10-29 | 1971-04-28 | Smith Kline French Lab | Derives de l'amidine |
| US3808336A (en) * | 1970-06-25 | 1974-04-30 | Smithkline Corp | Pharmaceutical compositions and methods of inhibiting histamine activity with thiourea derivatives |
| US3734924A (en) * | 1970-10-14 | 1973-05-22 | Smith Kline French Lab | Carboxamidines |
| GB1338169A (en) * | 1971-03-09 | 1973-11-21 | Smith Kline French Lab | Ureas thioureas and guanidines |
| GB1421999A (en) | 1973-02-08 | 1976-01-21 | Smith Kline French Lab | Heterocyclic containing sulphoxides |
| US4056620A (en) * | 1973-02-08 | 1977-11-01 | Smith Kline & French Laboratories Limited | Sulphoxides |
| US4046907A (en) * | 1973-05-17 | 1977-09-06 | Smith Kline & French Laboratories Limited | Imidazole alkylaminoethylene compounds |
| US4025527A (en) * | 1973-07-13 | 1977-05-24 | Smith Kline & French Laboratories Limited | Certain thiazoles and oxazoles |
| GB1533380A (en) * | 1974-09-02 | 1978-11-22 | Smith Kline French Lab | Process for the preparation of heterocyclic substituted thioureas and h-cyanoguanidines |
| US4140783A (en) * | 1976-05-24 | 1979-02-20 | Smith Kline & French Laboratories Limited | Isothiazole and isoxazole sulphoxides |
| GB1602458A (en) | 1977-05-05 | 1981-11-11 | Smith Kline French Lab | Bisamidines as histamine h2-antagonists |
-
1976
- 1976-03-11 GB GB9750/76A patent/GB1574214A/en not_active Expired
-
1977
- 1977-02-01 MW MW9/77A patent/MW977A1/xx unknown
- 1977-02-19 IN IN249/CAL/77A patent/IN147036B/en unknown
- 1977-02-21 ZA ZA00771018A patent/ZA771018B/xx unknown
- 1977-02-21 NZ NZ183396A patent/NZ183396A/xx unknown
- 1977-02-24 IL IL51530A patent/IL51530A/xx unknown
- 1977-03-01 PT PT66255A patent/PT66255B/pt unknown
- 1977-03-01 GR GR52885A patent/GR62562B/el unknown
- 1977-03-02 US US05/773,590 patent/US4118502A/en not_active Expired - Lifetime
- 1977-03-04 DK DK96477A patent/DK96477A/da unknown
- 1977-03-04 CA CA273,246A patent/CA1075700A/en not_active Expired
- 1977-03-07 IT IT21018/77A patent/IT1075494B/it active
- 1977-03-07 FR FR7706594A patent/FR2343730A1/fr active Granted
- 1977-03-08 AT AT154177A patent/AT358576B/de not_active IP Right Cessation
- 1977-03-08 ZM ZM26/77A patent/ZM2677A1/xx unknown
- 1977-03-08 FI FI770736A patent/FI770736A/fi unknown
- 1977-03-09 DE DE19772710326 patent/DE2710326A1/de not_active Withdrawn
- 1977-03-09 RO RO7789634A patent/RO73006A/ro unknown
- 1977-03-09 DD DD7700197753A patent/DD128616A5/xx unknown
- 1977-03-09 NL NL7702533A patent/NL7702533A/xx not_active Application Discontinuation
- 1977-03-10 JP JP2688377A patent/JPS52136170A/ja active Pending
- 1977-03-10 LU LU76930A patent/LU76930A1/xx unknown
- 1977-03-10 AU AU23155/77A patent/AU506146B2/en not_active Expired
- 1977-03-10 NO NO770854A patent/NO770854L/no unknown
- 1977-03-10 HU HU77SI1563A patent/HU176611B/hu unknown
- 1977-03-10 CS CS771613A patent/CS196352B2/cs unknown
- 1977-03-10 PL PL1977196568A patent/PL105620B1/pl unknown
- 1977-03-10 BE BE175676A patent/BE852324A/xx not_active IP Right Cessation
- 1977-03-11 OA OA56097A patent/OA05595A/xx unknown
- 1977-03-11 IE IE539/77A patent/IE44786B1/en unknown
- 1977-03-11 AR AR266827A patent/AR218242A1/es active
- 1977-03-11 SU SU772460625A patent/SU814274A3/ru active
- 1977-03-11 SE SE7702771A patent/SE7702771L/xx unknown
- 1977-03-11 ES ES456735A patent/ES456735A1/es not_active Expired
-
1978
- 1978-11-10 AR AR274409A patent/AR219955A1/es active
-
1979
- 1979-01-05 SU SU792705004A patent/SU731896A3/ru active
- 1979-08-10 US US06/065,478 patent/US4308275A/en not_active Expired - Lifetime
-
1981
- 1981-08-10 US US06/291,196 patent/US4395419A/en not_active Expired - Lifetime
-
1983
- 1983-03-07 US US06/472,434 patent/US4438127A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1263114A (en) | Derivatives of 1,2,5-thiadiazole-1-oxides and 1,1- dioxides as histamine h2-antagonists | |
| US4013678A (en) | Process for preparing heterocyclicalkylthioalkyl-n-cyanoguanidines | |
| US7678815B2 (en) | Thiazole-4-carboxyamide derivatives | |
| SE416049B (sv) | Forfarande for framstellning av 1,1-diaminoctylenderivat, som kan anvendas for hemning av vissa histaminverkningar | |
| IL97565A (en) | Processes for the preparation of 2-chloro-5-) chloromethyl or aminomethyl (thiazole and aminomethylthiazole salts | |
| USRE29668E (en) | Glycineamides | |
| NO770854L (no) | Fremgangsm}te for fremstilling av histamin h2-antagonister | |
| PL118387B1 (en) | Process for preparing novel derivatives of thiadiazole | |
| CA1053242A (en) | Heterocyclic guanidine derivatives | |
| KR100707320B1 (ko) | 신규 아미노티아졸 유도체, 이의 제조 방법 및 이를함유하는 제약 조성물 | |
| NO762661L (es) | ||
| WO2001064675A1 (en) | Condensed thiazolamines and their use as neuropeptide y5 antagonists | |
| US4093621A (en) | Process for preparing heterocyclicalkylthioalkyl-N-cyanoguanidines and thioureas | |
| CA1164876A (en) | Process for the preparation of cimetidine | |
| GB2125404A (en) | Thiazole derivatives | |
| US4728655A (en) | Sulfonamidines, process for the production thereof and pharmaceutical compositions containing the same | |
| CS203102B2 (en) | Process for preparing thiazolyl compounds | |
| JPS5936674A (ja) | Ｎ−置換グアニジノチアゾ−ル誘導体およびその製造法 | |
| NO148556B (no) | Analogifremgangsmaate for fremstilling av farmakologisk aktive triazinoner. | |
| US4189488A (en) | Amidinoformic and amidinosulphinic acids | |
| US4501747A (en) | Certain amide derivatives of 2-guanidino-thiazoles and compositions containing same | |
| US4171325A (en) | Chemical process | |
| CA2144545A1 (en) | Novel condensed thiazole derivative, production process thereof and pharmaceutical composition thereof | |
| US4090026A (en) | Certain nitrogen heterocyclic isothiocyanate esters | |
| NO851219L (no) | Sulfamoylguanidinderivater. |